Director Richard Heyman receives 19,234 Enliven (ELVN) stock options

Rhea-AI Filing Summary

Enliven Therapeutics director Richard A. Heyman received a grant of stock options for 19,234 shares of Enliven common stock. The options have an exercise price of $0.00 per share. They vest 100% on the earlier of the first anniversary of the 2026 annual stockholder meeting or the 2027 annual stockholder meeting, as long as he continues serving as a non-employee director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyman Richard A.

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$27.16	02/12/2026		A		19,234		(1)	02/12/2036	Common Stock	19,234	$0	19,234	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date.

	/s/ Ben Hohl, by power of attorney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Enliven Therapeutics (ELVN) report for Richard A. Heyman?

Enliven Therapeutics reported that director Richard A. Heyman received a grant of stock options for 19,234 shares at an exercise price of $0.00 per share. This reflects an equity-based compensation award rather than an open-market purchase or sale of existing common stock.

How many Enliven Therapeutics (ELVN) stock options were granted to Richard A. Heyman?

Richard A. Heyman was granted stock options covering 19,234 shares of Enliven Therapeutics common stock. These options were reported as a derivative security award and represent a new grant rather than a transaction involving already outstanding shares in the market.

What is the exercise price of Richard A. Heyman’s Enliven Therapeutics (ELVN) stock options?

The stock options granted to Richard A. Heyman have an exercise price of $0.00 per share. This means he does not pay additional cash to exercise the options, which are structured as a compensatory equity award tied to his service as a non-employee director.

When do Richard A. Heyman’s Enliven Therapeutics (ELVN) stock options vest?

All 19,234 stock options vest 100% on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting. Vesting requires that he continue as a non-employee director through the applicable vesting date.

What service condition applies to Richard A. Heyman’s Enliven Therapeutics (ELVN) option grant?

The option grant is subject to a service-based condition requiring Richard A. Heyman to remain a non-employee director through the vesting date. If he continues serving until the earlier specified annual meeting date, the entire 19,234-share option award will fully vest at that time.

Is Richard A. Heyman’s Enliven Therapeutics (ELVN) transaction a buy or sell of common stock?

The reported transaction is an acquisition of derivative securities, specifically a grant of stock options, not a market buy or sell of common stock. It reflects equity compensation awarded to Richard A. Heyman in his capacity as a non-employee director of Enliven Therapeutics.